Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation

Recently, higher extramedullary relapse rates following allogeneic stem cell transplantation (SCT) in myeloid malignancies were reported e.g. because of selection of poor-risk patients. We analysed five consecutive patients with post-transplant extramedullary relapse of chronic myeloid leukemia (CML) out of a total of 24 patients (21%) undergoing allo-SCT. All five patients with extramedullary relapse had clonal evolution and a history of blast phase (BP). In particular, 56% of the patients in BP had extramedullary relapse with no extramedullary relapse in patients with chronic/accelerated phase. Most frequent manifestation sites were the skeletal system, the muscles/subcutaneous tissue and the central nervous system. In one case chloroma was mimicking myositis of the lower limbs. Combined approaches were performed including irradiation (n = 4), chemotherapy (n = 2), IM (n = 2), dasatinib (n = 4), nilotinib (n = 1), a novel aurora-kinase-inhibitor (n = 1), donor lymphocytes (n = 2) or a second allo-SCT (n = 2). Transient response was achieved in one case, stable partial remissions in two cases, whereas two cases were refractory. Research should focus on prospective studies aiming to improve treatment of extramedullary relapse in stem cell recipients with CML with a special focus on the role of second generation tyrosine kinase inhibitors.

[1]  S. Mustjoki,et al.  Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.

[2]  Ming-Huang Chen,et al.  Comparison of Myeloablative and Nonmyeloablative Hematopoietic Stem Cell Transplantation for Treatment of Chronic Myeloid Leukemia , 2007, International journal of hematology.

[3]  O. Haas,et al.  Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy , 2007, European journal of clinical investigation.

[4]  T. Owonikoko,et al.  Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant , 2007, Nature Clinical Practice Oncology.

[5]  M. Horger,et al.  Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults. , 2007, AJR. American journal of roentgenology.

[6]  M. Horowitz,et al.  Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia , 2007, British journal of haematology.

[7]  James D. Griffin,et al.  Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia , 2007, Nature Reviews Cancer.

[8]  O. Ayyıldız,et al.  Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report , 2007, Journal of Neuro-Oncology.

[9]  M. Talpaz,et al.  Strategies for overcoming imatinib resistance in chronic myeloid leukemia , 2007, Leukemia & lymphoma.

[10]  D. Frame.  Chronic myeloid leukemia: standard treatment options. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[12]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[13]  M. Qazilbash,et al.  Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia , 2006, Bone Marrow Transplantation.

[14]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[15]  S. Amadori,et al.  Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. , 2006, Blood.

[16]  N. Kröger,et al.  Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study , 2006, European journal of haematology.

[17]  S. Paydaş,et al.  Granulocytic sarcoma: 32 cases and review of the literature , 2006, Leukemia & lymphoma.

[18]  I. Cunningham.  A clinical review of breast involvement in acute leukemia , 2006, Leukemia & lymphoma.

[19]  C. Martínez,et al.  Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors. The Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético) , 2005, Bone Marrow Transplantation.

[20]  B. Horisberger,et al.  Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey , 2004, Bone Marrow Transplantation.

[21]  C. Chai,et al.  Chloroma of the Testis After Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report , 2004, The Kaohsiung journal of medical sciences.

[22]  N. Hino,et al.  Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib. , 2004, Internal medicine.

[23]  F. Mancini,et al.  Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. , 2004, Haematologica.

[24]  J. Lister,et al.  Localized Lymphoid Relapse in the Pancreas Following Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myelogenous Leukemia , 2003, Leukemia & lymphoma.

[25]  Y. Ikeda,et al.  Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid , 2002, British journal of haematology.

[26]  R. Brand,et al.  Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. , 2002, Blood.

[27]  M. Bernard,et al.  Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. , 2002, Blood.

[28]  W. Poewe,et al.  Low concentrations of STI571 in the cerebrospinal fluid: a case report , 2002, British journal of haematology.

[29]  Juwon Park,et al.  Isolated extramedullary relapse in the pleural fluid of a patient with acute myeloid leukemia following allogeneic BMT , 2002, Bone Marrow Transplantation.

[30]  K. Friedrich,et al.  Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma , 2002, Annals of Hematology.

[31]  J. Tuscano,et al.  Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant , 2002, Annals of Hematology.

[32]  N. Kröger,et al.  Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. , 2001, Journal of hematotherapy & stem cell research.

[33]  R. Sabit,et al.  Haematopoietic stem cell transplantation. , 2000, Transfusion science.

[34]  D. Schenkein,et al.  Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation , 1999, Cancer.

[35]  M. Beksac,et al.  A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  T. Hwang,et al.  Granulocytic sarcoma as isolated extramedullary relapse after donor lymphocyte infusion in a patient with CML who relapsed after allogeneic bone marrow transplantation: a case report. , 1998, Journal of Korean medical science.

[37]  R. Liang,et al.  Isolated extramedullary relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia , 1998, Bone Marrow Transplantation.

[38]  C. Francastel,et al.  NF-E2p18/mafK is required in DMSO-induced differentiation of Friend erythroleukemia cells by enhancing NF-E2 activity , 1997, Leukemia.

[39]  J. Rowley,et al.  Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies. , 1997, Leukemia.

[40]  A. Gratwohl,et al.  Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. , 1996, Bone marrow transplantation.

[41]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[42]  J. Byrd,et al.  Recurrent granulocytic sarcoma. An unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule , 1994, Cancer.

[43]  T. Lister,et al.  The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. , 1982, Medical and pediatric oncology.